Literature DB >> 22392350

Effect of ascorbic acid on reactive oxygen species production in chemotherapy and hyperthermia in prostate cancer cells.

Hidenobu Fukumura1, Motohiko Sato, Kyouhei Kezuka, Itaru Sato, Xianfeng Feng, Satoshi Okumura, Takayuki Fujita, Utako Yokoyama, Haruki Eguchi, Yoshihiro Ishikawa, Tomoyuki Saito.   

Abstract

Cellular reactive oxygen species (ROS) production is increased by both temperature and anticancer drugs. Antioxidants are known to suppress ROS production while cancer patients may take them as dietary supplement during chemotherapy and hyperthermic therapy. We examined changes in ROS production in prostate cancer cells in the presence of various anticancer drugs and antioxidants at different temperatures. ROS production was increased with temperature in cancer cells, but not in normal cells; this increase was potently inhibited by ascorbic acid. ROS production was also increased in the presence of some anticancer drugs, such as vinblastine, but not by others. Dietary antioxidant supplements, such as β-carotene, showed variable effects. Ascorbic acid potently inhibited ROS production, even in the presence of anticancer drugs, while β-carotene showed no inhibition. Accordingly, our results suggest that cancer patients should carefully choose antioxidants during their cancer chemotherapy and/or hyperthermic therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22392350     DOI: 10.1007/s12576-012-0204-0

Source DB:  PubMed          Journal:  J Physiol Sci        ISSN: 1880-6546            Impact factor:   2.781


  29 in total

1.  Treatment for intermediate and high-risk prostate cancer: controversial issues and the role of hyperthermia.

Authors:  Sergio Maluta; Stefano Dall'oglio; Luisa Nadalini
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

Review 2.  Drug delivery systems for differential release in combination therapy.

Authors:  Hongbin Zhang; Guojie Wang; Huai Yang
Journal:  Expert Opin Drug Deliv       Date:  2011-01-13       Impact factor: 6.648

Review 3.  Drug development for cancer chemoprevention: focus on molecular targets.

Authors:  Karen A Johnson; Powel H Brown
Journal:  Semin Oncol       Date:  2010-08       Impact factor: 4.929

4.  Roles of NADPH oxidases in cisplatin-induced reactive oxygen species generation and ototoxicity.

Authors:  Hyung-Jin Kim; Jeong-Han Lee; Se-Jin Kim; Gi Su Oh; Hae-Dalma Moon; Kang-Beom Kwon; Channy Park; Byung Hyun Park; Ho-Kyun Lee; Sang-Young Chung; Raekil Park; Hong-Seob So
Journal:  J Neurosci       Date:  2010-03-17       Impact factor: 6.167

5.  Cisplatin induces duplex 3' overhangs and 5' blunt ends in epididymal epithelium in a Bax-dependent manner without any protection from L-ascorbic acid.

Authors:  Kilarkaje Narayana
Journal:  Eur J Pharmacol       Date:  2010-06-04       Impact factor: 4.432

6.  Mitochondrial DNA damage is sensitive to exogenous H(2)O(2) but independent of cellular ROS production in prostate cancer cells.

Authors:  Sam W Chan; Phuong-Nam Nguyen; David Ayele; Simone Chevalier; Armen Aprikian; Junjian Z Chen
Journal:  Mutat Res       Date:  2011-08-05       Impact factor: 2.433

7.  N-acetylcysteine inhibits proliferation, adhesion, migration and invasion of human bladder cancer cells.

Authors:  Athikom Supabphol; Verasing Muangman; Warinthorn Chavasiri; Roongtawan Supabphol; Wandee Gritsanapan
Journal:  J Med Assoc Thai       Date:  2009-09

Review 8.  The controversial place of vitamin C in cancer treatment.

Authors:  J Verrax; P Buc Calderon
Journal:  Biochem Pharmacol       Date:  2008-09-30       Impact factor: 5.858

Review 9.  Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials.

Authors:  Keith I Block; Amanda C Koch; Mark N Mead; Peter K Tothy; Robert A Newman; Charlotte Gyllenhaal
Journal:  Cancer Treat Rev       Date:  2007-03-23       Impact factor: 12.111

10.  Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro.

Authors:  C M Kurbacher; U Wagner; B Kolster; P E Andreotti; D Krebs; H W Bruckner
Journal:  Cancer Lett       Date:  1996-06-05       Impact factor: 8.679

View more
  17 in total

1.  Effects of food diameter on bite size per mouthful and chewing behavior.

Authors:  Kouichi Shiozawa; Yoshiki Ohnuki; Yasumasa Mototani; Daisuke Umeki; Aiko Ito; Yasutake Saeki; Nobuhiro Hanada; Satoshi Okumura
Journal:  J Physiol Sci       Date:  2016-01       Impact factor: 2.781

2.  Hyperthermia generated with ferucarbotran (Resovist®) in an alternating magnetic field enhances cisplatin-induced apoptosis of cultured human oral cancer cells.

Authors:  Itaru Sato; Masanari Umemura; Kenji Mitsudo; Mitomu Kioi; Hideyuki Nakashima; Toshinori Iwai; Xianfeng Feng; Kayoko Oda; Akiyoshi Miyajima; Ayako Makino; Maki Iwai; Takayuki Fujita; Utako Yokoyama; Satoshi Okumura; Motohiko Sato; Haruki Eguchi; Iwai Tohnai; Yoshihiro Ishikawa
Journal:  J Physiol Sci       Date:  2014-03-12       Impact factor: 2.781

Review 3.  Nutritional countermeasures targeting reactive oxygen species in cancer: from mechanisms to biomarkers and clinical evidence.

Authors:  Anatoly Samoylenko; Jubayer Al Hossain; Daniela Mennerich; Sakari Kellokumpu; Jukka Kalervo Hiltunen; Thomas Kietzmann
Journal:  Antioxid Redox Signal       Date:  2013-04-15       Impact factor: 8.401

4.  Magnetite nanoparticles coated with oleic acid: accumulation in hepatopancreatic cells of the mangrove crab Ucides cordatus.

Authors:  Hector Aguilar Vitorino; Priscila Ortega; Roxana Y Pastrana Alta; Flavia Pinheiro Zanotto; Breno Pannia Espósito
Journal:  Environ Sci Pollut Res Int       Date:  2018-10-24       Impact factor: 4.223

5.  A magnetic anti-cancer compound for magnet-guided delivery and magnetic resonance imaging.

Authors:  Haruki Eguchi; Masanari Umemura; Reiko Kurotani; Hidenobu Fukumura; Itaru Sato; Jeong-Hwan Kim; Yujiro Hoshino; Jin Lee; Naoyuki Amemiya; Motohiko Sato; Kunio Hirata; David J Singh; Takatsugu Masuda; Masahiro Yamamoto; Tsutomu Urano; Keiichiro Yoshida; Katsumi Tanigaki; Masaki Yamamoto; Mamoru Sato; Seiichi Inoue; Ichio Aoki; Yoshihiro Ishikawa
Journal:  Sci Rep       Date:  2015-03-17       Impact factor: 4.379

6.  Simultaneous hyperthermia-chemotherapy with controlled drug delivery using single-drug nanoparticles.

Authors:  Itaru Sato; Masanari Umemura; Kenji Mitsudo; Hidenobu Fukumura; Jeong-Hwan Kim; Yujiro Hoshino; Hideyuki Nakashima; Mitomu Kioi; Rina Nakakaji; Motohiko Sato; Takayuki Fujita; Utako Yokoyama; Satoshi Okumura; Hisashi Oshiro; Haruki Eguchi; Iwai Tohnai; Yoshihiro Ishikawa
Journal:  Sci Rep       Date:  2016-04-22       Impact factor: 4.379

7.  A novel osteoporosis model with ascorbic acid deficiency in Akr1A1 gene knockout mice.

Authors:  Cheng-Wei Lai; Hsiao-Ling Chen; Min-Yu Tu; Wei-Yu Lin; Theresa Röhrig; Shang-Hsun Yang; Ying-Wei Lan; Kowit-Yu Chong; Chuan-Mu Chen
Journal:  Oncotarget       Date:  2017-01-31

8.  Hyperthermia and chemotherapy using Fe(Salen) nanoparticles might impact glioblastoma treatment.

Authors:  Makoto Ohtake; Masanari Umemura; Itaru Sato; Taisuke Akimoto; Kayoko Oda; Akane Nagasako; Jeong-Hwan Kim; Takayuki Fujita; Utako Yokoyama; Tomohiro Nakayama; Yujiro Hoshino; Mai Ishiba; Susumu Tokura; Masakazu Hara; Tomoya Muramoto; Sotoshi Yamada; Takatsugu Masuda; Ichio Aoki; Yasushi Takemura; Hidetoshi Murata; Haruki Eguchi; Nobutaka Kawahara; Yoshihiro Ishikawa
Journal:  Sci Rep       Date:  2017-02-20       Impact factor: 4.379

9.  p53 is a key regulator for osthole-triggered cancer pathogenesis.

Authors:  Ssu-Ming Huang; Cheng-Fang Tsai; Dar-Ren Chen; Min-Ying Wang; Wei-Lan Yeh
Journal:  Biomed Res Int       Date:  2014-06-12       Impact factor: 3.411

10.  Synthesis and Evaluation of Folate-Conjugated Phenanthraquinones for Tumor-Targeted Oxidative Chemotherapy.

Authors:  Ajay Kumar; Venkatesh Chelvam; Mahalingam Sakkarapalayam; Guo Li; Pedro Sanchez-Cruz; Natasha S Piñero; Philip S Low; Antonio E Alegria
Journal:  Open J Med Chem       Date:  2016-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.